UCLA research unlocks how melanoma can resist newly approved drug combo therapy

UCLA scientists discovered how melanoma builds up resistance to drug therapy combos that utilize BRAF+MEK inhibitors (chemical compounds used to fight cancer). The two-year study analyzed tumor samples from patients before being prescribed the drug therapy. Click here to read the full press release. ### Among the research institutions NCI funds across the United States, … Continue reading “UCLA research unlocks how melanoma can resist newly approved drug combo therapy”

UCLA scientists discovered how melanoma builds up resistance to drug therapy combos that utilize BRAF+MEK inhibitors (chemical compounds used to fight cancer). The two-year study analyzed tumor samples from patients before being prescribed the drug therapy.

Click here to read the full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply